All Posts
Rare Cancer Day
October 1 is Rare Cancer Day as proclaimed by the National Organization for Rare Disorders (NORD). The NORD website shares…
Minneapolis Meetup
As the "instigator" who 11 years ago blissfully started getting mothers of active-duty Marines and eventually Marine vets to meet…
Bank of America Chicago Marathon
Marathon - Sunday, October 13, 2024 Chicago, Illinois The fundraising minimum for the 2024 Bank of America Chicago Marathon is…
Suggested Reading - Graeber
Charles Graeber, The Breakthrough: Immunotherapy and the Race to Cure Cancer, Twelve, 2018. “Cancer kills millions of people every year…
Why Jan & Dean Meyer Gave $125,000 to the Cholangiocarcinoma Foundation, and why they hope others will too
“Cholangiocarcinoma sucks, it’s a tough, tough cancer. Being difficult to diagnose, often diagnosed in later stages, and having limited treatment options,…
AMMF, Cholangiocarcinoma Foundation, TargetCancer Foundation, and The Bili Project, Award Unique Collaborative Grant
Read the full article by clicking here.
Debora Mae (Lankford) Waite
Debora Mae (Lankford) Waite age 49, passed away peacefully in her home surrounded by family on August 31, 2019 after…
Justin S. Lee
5/1/1950 – 9/2/2019 On September 2, 2019, we lost our beloved father and husband to cholangiocarcinoma (bile duct) cancer after…
University of Chicago Regional Symposium
Join us for an afternoon dedicated to the science of cholangiocarcinoma. The symposium will include presentations from the University of…
A Phase 3, First Line Study of Pemigatinib vs Gemcitabine/Cisplatin in Patients with Cholangiocarcinoma
Study Name A Phase 3, First Line Study of Pemigatinib vs Gemcitabine/Cisplatin in Patients with Cholangiocarcinoma ClinicalTrials.gov Identifier (if applicable)…